Core Insights - Yangtze River Pharmaceutical Group has achieved the EFQM "Seven Stars Certification," marking a significant milestone in its development journey, just 50 months after receiving the EFQM Global Award "Five Stars" [1][5] - The certification reflects the company's strong capabilities in enterprise management and its commitment to high-quality development [1][5] Group 1: Achievements and Recognition - The EFQM Global Award is one of the three major quality awards globally, serving as a benchmark for companies to assess their management maturity [5] - Since obtaining the "Five Stars" honor in 2021, the company has continued to pursue excellence through initiatives focused on quality enhancement and internal capabilities [5][6] - The company has launched several initiatives, including "Learning Year," "Digital Intelligence Year," "Compliance Year," and "Health Year," to strengthen various management systems [5][6] Group 2: Evaluation Process - The on-site evaluation for the "Seven Stars Certification" took place from April 14 to 18, involving five global experts from Germany, the UK, Portugal, Spain, and China [5][6] - The evaluation covered multiple dimensions, including strategic execution, cultural implementation, innovation mechanisms, and operational performance, with 30 interview sessions and over 450 questions asked [5][6] Group 3: Future Plans - Following the certification, the company aims to enhance its capabilities further and is set to pursue the "Six Diamonds" EFQM Global Award in 2024 [5][6] - The company plans to leverage this achievement as a new starting point for comprehensive improvement and to deepen the application of the EFQM model [6] - The company is committed to building a "Harmonious" ecosystem and learning from global best practices to advance towards becoming a world-class pharmaceutical and health industry group [6]